Targeting Sleep Homeostasis to Improve Alcohol Use Disorder Treatment Outcomes (M-STAR Study)

Sponsor
University of Michigan (Other)
Overall Status
Recruiting
CT.gov ID
NCT04457674
Collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH)
150
1
2
45.8
3.3

Study Details

Study Description

Brief Summary

Insomnia is common in people who are in treatment for alcohol use disorder. It can impact both sleep quality and daytime functioning, as well as make it harder to treat the underlying alcohol use disorder. This study is looking at two types of therapy to help manage insomnia specifically for people also in treatment for alcohol use disorder.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive Behavioral Therapy for insomnia (CBTi)
  • Behavioral: Sleep Hygiene Education (SHE)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Targeting Sleep Homeostasis to Improve Alcohol Use Disorder Treatment Outcomes
Actual Study Start Date :
Nov 7, 2020
Anticipated Primary Completion Date :
Aug 31, 2024
Anticipated Study Completion Date :
Aug 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: Cognitive Behavioral Therapy for insomnia (CBTi)

CBTi is a non-medication therapy that includes cognitive and behavioral treatment components.

Behavioral: Cognitive Behavioral Therapy for insomnia (CBTi)
CBTi consists of six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.

Other: Sleep Hygiene Education (SHE)

SHE is a non-medication therapy that focuses on identifying and changing several behavioral and environmental factors that can interfere with sleep.

Behavioral: Sleep Hygiene Education (SHE)
SHE participants receive six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.

Outcome Measures

Primary Outcome Measures

  1. Score from the insomnia severity index (ISI) [Immediately post treatment]

    The ISI is a 7-item self-report assessment of the nature, severity and impact of insomnia. Scores range from 0-28 with higher scores suggesting more clinically significant insomnia.

  2. Percent days abstinent from alcohol as documented in the timeline follow-back (TLFB) [Immediately post treatment]

    The Alcohol TLFB is an interviewer-based drinking assessment method to estimate drinking behaviors, including both frequency and quantity of consumption.

Secondary Outcome Measures

  1. Score from Multidimensional Fatigue Inventory (MFI), General Fatigue sub-scale [Immediately post treatment]

    The MFI is a 20-item assessment that provides an overall fatigue score (20-100) in addition to 5 separate dimensions of fatigue: general fatigue, physical fatigue, reduced motivation, reduced activity, and mental fatigue. Sub-scale scores range from 4-20 with higher scores indicating higher levels of fatigue.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Meet probable Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for Alcohol Use Disorder with ≤12 weeks of abstinence

  • Planned enrollment into an abstinence-based treatment program

  • Meet probable DSM-5 criteria for chronic insomnia, confirmed with sleep diary

  • Ability to travel to Ann Arbor for sleep laboratory assessments

  • Access to a video chat-capable device and reliable Wi-Fi network

Exclusion Criteria:
  • Diagnosis of, or high suspicion for, sleep disorders other than insomnia

  • Meet probable DSM-5 criteria for bipolar disorder, psychotic disorder, or post-traumatic stress disorder (PTSD)

  • Terminal or progressive physical illness (e.g., cancer), neurological degenerative disease (e.g., dementia), or presence of an unstable medical condition that is the specific cause of insomnia

  • Self-reported pregnancy or intention to become pregnant during the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 The University of Michigan Ann Arbor Michigan United States 48109

Sponsors and Collaborators

  • University of Michigan
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Investigators

  • Principal Investigator: J Todd Arnedt, Ph.D., University of Michigan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
J. Todd Arnedt, Associate Professor of Psychiatry, University of Michigan
ClinicalTrials.gov Identifier:
NCT04457674
Other Study ID Numbers:
  • HUM00173631
  • R01AA028158
First Posted:
Jul 7, 2020
Last Update Posted:
Aug 22, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by J. Todd Arnedt, Associate Professor of Psychiatry, University of Michigan
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2022